Presented By:
Dr. Philip Molloy, MD
Speaker Biography:
Born in Boston, MA, current resident of Plymouth, MA Undergraduate degree from Bowdoin College, Magna cum laude MD degree from Tufts, 1981 Internal Medicine Residency at the University of Minnesota 1981-1984 Rheumatology/Clinical Immunology Fellowship at Tufts 1984-1986 Practicing Rheumatologist, Plymouth, MA, & Nantucket Cottage Hospital, since 1986 Medical Director of Tick-borne diseases, Imugen 1997-2020, then at Sonic Northeast since 2020 Dr. Molloy has a longstanding clinical and research interest in Lyme and other Tick-borne diseases, ever since his fellowship under Dr Allen Steere, the discoverer of Lyme disease. He has participated in numerous research protocols on Lyme disease and associated tick borne infections, including the treatment of Lyme arthritis; the development of laboratory tests to distinguish Lyme disease from the Lyme vaccine serological response; blood tests for screening blood donors for Babesia; and in characterizing and diagnosing B.miyamotoi. General rheumatology research interests have also included treatments and monitoring disease activity/outcomes in rheumatoid arthritis; and clinical trials for therapeutic interventions for osteoporosis, rheumatoid arthritis and osteoarthritis.
Webinar:
Update on the Laboratory Diagnosis of Lyme and Other Tick-borne Diseases (TBDs)
Webinar Abstract:
There has been a major development in the serologic diagnosis of Lyme disease. All parties agree (as before) on the paradigm of “Two Tier Testing”. The “Old” recommendation is called STTT, or Standard Two Tier Testing (ELISA reflexed to IgG and IgM WB). There are well known drawbacks and problems with this, acknowledged by the CDC and many specialists in the field. This led to the development and adoption of an improved paradigm called MTTT, or Modified Two Tier Testing. Modified Two Tiered Testing is well validated, the associated tests have been FDA cleared and they’ve been shown to perform equal to or superior to STTT in all stages of Lyme infection.
Another change is the continued appreciation of co-infections (one tick bite transmitting multiple pathogens), with implications of the types of diagnostic tests, including the available PCR tests, to be ordered in symptomatic persons following tick bites. Finally, there continues to be new emerging TBDs, including Anaplasma, Babesia, and Ehrlichia, plus further geographic spread of the more traditional well-known agents.
Earn PACE Credits:
1. Make sure you're a registered member of LabRoots ([ Ссылка ])
2. Watch the webinar on the LabRoots Website ([ Ссылка ])
3. Click Here to get your PACE credits (Expiration date – APR 02, 2023): ([ Ссылка ])
LabRoots on Social:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Pinterest: [ Ссылка ]
SnapChat: labroots_inc
